Pneumonia - Prevention and Adjunctive Therapies

Prevention and Treatment of Pneumonia Introduction Pneumonia prevention and treatment require a comprehensive approach combining vaccination, medication prophylaxis, and lifestyle modifications. This section covers the key strategies for preventing pneumonia across different age groups and risk factors, as well as evidence-based treatment approaches for various types of pneumonia. Vaccination Strategies Vaccination is among the most effective ways to prevent pneumonia. Several vaccines are recommended to reduce the risk of infection. Influenza Vaccination Annual influenza vaccination is recommended for all persons six months of age and older. The influenza vaccine is particularly important because influenza can cause primary viral pneumonia and increases the risk of secondary bacterial superinfection, including pneumococcal pneumonia. Pneumococcal Vaccination in Children Pneumococcal conjugate vaccines are routinely given to children younger than two years of age. These vaccines use a protein-polysaccharide conjugate approach, which means they attach polysaccharide antigens from the bacterial capsule to a protein carrier. This conjugate design makes them more effective at triggering immune responses in young children, who respond poorly to polysaccharide vaccines alone. The introduction of these conjugate vaccines has led to marked declines in invasive pneumococcal disease. Beyond direct protection of vaccinated children, these vaccines reduce disease in older adults through herd immunity—when a large portion of the population is vaccinated, unvaccinated individuals benefit because transmission is reduced overall. Pneumococcal Vaccination in Adults For adults, pneumococcal polysaccharide vaccine is recommended for those aged 50 years and older, and for younger adults with high-risk medical conditions (such as chronic obstructive pulmonary disease, asthma, or diabetes). Recent guidance advises initiating pneumococcal vaccination at age 50 rather than 65, reflecting the significant burden of pneumococcal disease in this age group. Other Vaccines Vaccines against Haemophilus influenzae type b, pertussis, varicella (chickenpox), and measles also provide protection against pneumonias associated with these pathogens. Medication Prophylaxis Beyond vaccines, certain medications can prevent pneumonia in specific populations, particularly during disease outbreaks or in immunocompromised individuals. Antiviral Prophylaxis for Influenza Antiviral agents such as baloxavir or oseltamivir can be used to prevent influenza during outbreaks, particularly in healthcare settings or among household contacts of infected persons. These agents belong to a class called neuraminidase inhibitors. They work by blocking the viral neuraminidase enzyme, which normally releases newly formed influenza virus particles from infected cells. By blocking this enzyme, the medications prevent the spread of virus from cell to cell. Oseltamivir and inhaled zanamivir can be safely used for prophylaxis over extended periods, such as 16 weeks during a prolonged outbreak. Systematic reviews have confirmed that neuraminidase inhibitors effectively reduce the incidence of influenza when used for prevention. Prophylaxis for Pneumocystis Pneumonia Trimethoprim-sulfamethoxazole prophylaxis significantly reduces the risk of Pneumocystis pneumonia in people with HIV infection whose CD4 counts fall below 200 cells/µL. This medication is also useful for other severely immunocompromised patients. The rationale for prophylaxis in this population is that Pneumocystis jirovecii (the causative organism) is ubiquitous in the environment, and immunocompromised individuals are at extremely high risk for severe disease. Lifestyle and Environmental Measures Many cases of pneumonia can be prevented through practical lifestyle and environmental changes that reduce transmission or improve respiratory health. Respiratory Hygiene and Hand Washing Hand washing, coughing into one's sleeve (rather than one's hands or into the air), and wearing surgical masks when ill are simple but effective measures that decrease transmission of respiratory pathogens. These measures are particularly important during respiratory illness outbreaks. Smoking Cessation Smoking cessation markedly lowers the risk of pneumococcal pneumonia. Smoking damages the mucociliary clearance mechanism—the specialized cells and mucus in the respiratory tract that trap and eliminate pathogens—making the lungs more vulnerable to infection. Indoor Air Quality and Ventilation Reducing indoor air pollution from solid fuel cooking and improving ventilation lower pneumonia incidence, particularly in developing countries where solid fuel use is common. Indoor air pollution from cooking fires exposes the respiratory tract to harmful particles and irritants. Breastfeeding Exclusive breastfeeding during the first six months of life reduces both the risk and severity of pneumonia in infants. Breast milk contains maternal antibodies and other immune factors that protect developing infants. Special Preventive Measures for High-Risk Groups Certain populations benefit from additional preventive strategies tailored to their specific risks. Aspiration Pneumonia Prevention Good oral hygiene in frail elderly individuals may lower the risk of aspiration pneumonia. Aspiration pneumonia occurs when oropharyngeal contents—which contain oral bacteria—are inhaled into the lungs. By maintaining good oral hygiene, the burden of pathogenic bacteria in the oral cavity is reduced, lowering the risk of serious infection if aspiration occurs. <extrainfo> Zinc Supplementation in Children Zinc supplementation in children aged two months to five years appears to reduce pneumonia rates. This effect is thought to relate to zinc's role in immune function. </extrainfo> Antiviral Treatment of Influenza Pneumonia When influenza progresses to pneumonia, antiviral treatment should be initiated promptly. Effective Antiviral Agents Oseltamivir, zanamivir, peramivir, and baloxavir are all effective against influenza A and B when started within 48 hours of symptom onset. Treatment with neuraminidase inhibitors shortens the duration of flu symptoms in otherwise healthy patients. The 48-hour window is critical—starting treatment after symptoms have been present for two days is less likely to be beneficial. <extrainfo> Other Viral Pneumonias No specific antivirals are currently recommended for pneumonia caused by SARS coronavirus, adenovirus, hantavirus, or parainfluenza virus. Treatment of these viral pneumonias remains largely supportive, focusing on oxygen therapy and management of respiratory failure. </extrainfo> Bacterial Pneumonia: Antibiotics and Adjunctive Therapy Antibiotic Selection The choice of antibiotic for bacterial pneumonia depends on the suspected organism and the patient's risk factors. For community-acquired pneumonia (CAP), empiric coverage typically targets Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms such as Legionella or Mycoplasma. For hospital-acquired pneumonia, coverage must include more resistant organisms. Corticosteroids in Bacterial Pneumonia Corticosteroids have been shown to lower mortality in non-severe community-acquired pneumonia for both adults and children. However, recent guidance has evolved. The 2017 guidelines recommend corticosteroids for severe community-acquired pneumonia, while 2019 guidelines advise against routine use unless refractory shock is present. The role of corticosteroids in bacterial pneumonia remains nuanced, as they can reduce harmful inflammation but may theoretically impair immune response. Viral Pneumonia: Antibiotics and Steroids When to Use Antibiotics in Viral Pneumonia Some clinicians prescribe antibiotics in viral pneumonia to address possible bacterial superinfection, though current guidelines suggest withholding antibiotics in mild disease. The concern with antibiotics is that unnecessary use promotes antibiotic resistance and unnecessary adverse effects. However, in severe viral pneumonia or when bacterial coinfection is suspected, antibiotics may be appropriate. Corticosteroids in Viral Pneumonia The use of corticosteroids in viral pneumonia remains controversial and is not routinely recommended. Unlike in severe bacterial pneumonia, the evidence for corticosteroid benefit in viral pneumonia is weak, and theoretical concerns about impairing antiviral immune responses persist. Pneumocystis Pneumonia in HIV-Infected Individuals Adjunctive Corticosteroids In HIV-infected individuals with Pneumocystis pneumonia, adjunctive corticosteroids may improve outcomes. These patients face particular risk because of their compromised immune systems. The addition of corticosteroids to anti-Pneumocystis antibiotics has been shown to reduce mortality in some studies. Aspiration Pneumonia Distinguishing Aspiration Pneumonitis from Aspiration Pneumonia An important distinction must be made between aspiration pneumonitis and aspiration pneumonia. Aspiration pneumonitis occurs when sterile gastric contents (acidic material) are inhaled, causing a chemical injury to the lungs. This condition is treated conservatively without antibiotics, as there is no bacterial infection. Aspiration pneumonia, by contrast, occurs when oropharyngeal contents containing bacteria are aspirated into the lungs. Antibiotics are indicated only when aspiration leads to bacterial pneumonia—that is, when clinical and radiographic signs of pneumonia develop. Antibiotic Choices for Aspiration Pneumonia When antibiotics are indicated for aspiration pneumonia, common regimens include: Clindamycin (which covers anaerobic oral bacteria) A beta-lactam (such as amoxicillin-clavulanate) combined with metronidazole An aminoglycoside combined with anaerobic coverage Selection depends on the suspected organism and whether the pneumonia is community-acquired or hospital-acquired. Hospital-acquired aspiration pneumonia may involve more resistant organisms and typically requires broader spectrum coverage. Special Populations: HIV-Associated Pneumonia Children with HIV are at increased risk for community-acquired pneumonia and require vigilant monitoring. This increased risk reflects their compromised immune systems. Beyond standard prevention measures, these children may benefit from enhanced prophylaxis and earlier intervention with antibiotics when respiratory infections develop.